BerandaAAVXF • OTCMKTS
add
Abivax SA
Tutup sebelumnya
$11,05
Rentang tahun
$10,19 - $15,15
Kapitalisasi pasar
603,83 jt EUR
Rasio P/E
-
Hasil dividen
-
Bursa utama
EPA
Berita pasar
Keuangan
Laporan Pendapatan
Pendapatan
Laba bersih
| (EUR) | Jun 2024info | Perubahan Y/Y |
|---|---|---|
Pendapatan | 3,39 jt | 201,87% |
Biaya operasional | 43,39 jt | 119,55% |
Laba bersih | -40,82 jt | -57,14% |
Margin laba bersih | -1,20 rb | 47,94% |
Penghasilan per saham | — | — |
EBITDA | -39,91 jt | -114,56% |
Tarif pajak efektif | — | — |
Neraca
Total aset
Total liabilitas
| (EUR) | Jun 2024info | Perubahan Y/Y |
|---|---|---|
Investasi tunai jangka pdk | 222,32 jt | 94,37% |
Total aset | 284,49 jt | 66,29% |
Total liabilitas | 158,02 jt | 74,43% |
Total ekuitas | 126,47 jt | — |
Saham yang beredar | 62,92 jt | — |
Harga terhadap nilai buku | 5,50 | — |
Tingkat pengembalian aset | -35,15% | — |
Tingkat pengembalian modal | -41,69% | — |
Arus Kas
Perubahan kas bersih
| (EUR) | Jun 2024info | Perubahan Y/Y |
|---|---|---|
Laba bersih | -40,82 jt | -57,14% |
Kas dari operasi | -42,59 jt | -208,62% |
Kas dari investasi | 6,73 jt | 886,10% |
Kas dari pembiayaan | 20,16 jt | -65,46% |
Perubahan kas bersih | -14,81 jt | -133,88% |
Arus kas bebas | -21,07 jt | -45,88% |
Tentang
Abivax SA is a clinical stage biotechnology company focused on developing innovative treatments that harness the body’s natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases.
Abivax has one program in clinical development with its lead drug candidate, obefazimod, to treat ulcerative colitis. Another program in Crohn’s disease is also in preparation and other potential inflammatory indications are being evaluated.
The company’s headquarters are based in Paris, France with a US office in Waltham, MA. Abivax’s R&D work is conducted at its research center based in Montpellier, France. Wikipedia
Didirikan
4 Des 2013
Situs
Karyawan
62
